Lucie Blondeau

TL;DR: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.

TL;DR: Patients benefit from early, in-hospital initiation of colchicine after MI, as well as for urgent hospitalization for angina requiring revascularization and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke.

TL;DR: Improvements in quality of life and functional capacity were similar in patients with atrial fibrillation and CHF randomized to rhythm- versus rate-control strategies, and sinus rhythm was associated with beneficial effects on New York Heart Association functional class and modest gains inquality of life.

TL;DR: In secondary cardiovascular prevention, the addition of low-dose colchicine to standard medical therapy reduces the incidence of major cardiovascular events, except cardiovascular mortality, when compared tostandard medical therapy alone.

TL;DR: Cost-effectiveness analyses indicate that the addition of colchicine to standard-of-care therapy after myocardial infarction is economically dominant and therefore generates cost savings.